Zelenectide pevedotin
A tiny peptide instead of an antibody carries the same payload as Padcev to Nectin-4, with far less rash and neuropathy in early data, but its developer stepped back in 2026.
Duravelo-2 (randomised phase 2/3): encouraging responses and a differentiated safety profile (skin reactions ~4-fold lower, neuropathy half that of enfortumab vedotin), presented ASCO 2026. Bicycle Therapeutics deprioritised the programme in March 2026 after regulators indicated the trial design could not support registration.
Zelenectide pevedotin is a bicyclic-peptide toxin conjugate (no antibody); only the payload is shown.
1.Bicyclic peptide binds Nectin-4 with high affinity
- Route
- Intravenous
- Schedule
- 5 mg/m² weekly, 3 weeks on / 1 off (optimised dose), alone or with pembrolizumab
- Mar 2026WithdrawalUS
Programme deprioritised after regulatory feedback on Duravelo-2 design source
| Adverse event | Any grade | Grade 3+ |
|---|---|---|
| Fatigue | 40% | — |
| Skin reactions | 13% | — |
| Peripheral neuropathy | 25% | — |
Roughly one quarter the rate reported for enfortumab vedotin. Events listed without rates were not read from a primary source; see the label. Blank cells mean the figure was not sourced, not that it is zero.
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Zelenectide pevedotin" OR ABSTRACT:"Zelenectide pevedotin" OR TITLE:"BT8009" OR ABSTRACT:"BT8009") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Zelenectide pevedotin, not a curated reading list.
Pages like this
not linked directly; found by shared links- CompanyAktis Oncology
Shares Nectin-4, Bladder & urothelial cancer.
- TrialEV-303 / KEYNOTE-905
Shares Nectin-4, Bladder & urothelial cancer.
- TrialEV-302 / KEYNOTE-A39
Shares Nectin-4, Bladder & urothelial cancer.
- ProductAK146D1
Shares Nectin-4, Bladder & urothelial cancer.
- Key paperEV-302: enfortumab vedotin plus pembrolizumab replaces chemotherapy as first treatment for advanced bladder cancer
Shares Nectin-4, Bladder & urothelial cancer.
- TechnologyBispecific ADC
Shares Nectin-4, Bladder & urothelial cancer.
- ProductEnfortumab vedotin
Shares Nectin-4, Bladder & urothelial cancer.